Eli Lilly and Co to Provide Alzheimer's Disease Update Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the data. So I guess given the strong data you showed in the MCI patients in TRAILBLAZER-ALZ 2 and then I guess what you highlighted around baseline amyloid versus ARIA risk, it feels like the donanemab is arguably better suited earlier in the disease course. And given the long duration of TRAILBLAZER-ALZ 3, how should we think about interim looks and/or the potential to stop early? And then just on donanemab, just given the potential for amyloid negativity to drive treatment duration, how are you thinking about pricing models when this hit the market? Daniel M. Skovronsky - Eli Lilly and Company - Executive VP, Chief Scientific & Medical Officer and President of Lilly Research Laboratories Okay. I'll take the TRAILBLAZER-ALZ 3 question, and then Anne can take the pricing question. So you're right. We maybe painstakingly showed a number of analyses, all concordant on the idea that the earlier you treat, the bigger impact you can have on disease progression, which gives us confidence that TRAILBLAZER 3 should be successful. We've structured this as an event-driven study, and we can -- we have powered it for certain effect size, which we could be more optimistic about now. Having said that, we never -- we usually have an opportunity across our therapeutic areas in our Phase III trials for including interim analyses but we try to never comment on specifics of what or when that might look like because we don't want to unblind the study by then having to disclose things prematurely.

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Just one really remaining for me and most of them have been answered already, but just interested to get more detail on your views regarding the diagnostics approach for the disease. So perhaps you'll take a update on your approach, your collaboration with Roche. And then more conceptually, when we might ultimately be able to routinely rely on a blood-based biomarkers to diagnose this disease more broadly.